BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics released new clinical data on September 8 for its lead KRASG12C inhibitor BBO-8520 and said it will now prioritize pairing the drug with a checkpoint inhibitor in previously treated lung cancer patients, alongside combination work for its two earlier-stage assets, BBO-11818 and BBO-10203, in other KRAS-mutant tumors. The headline result was a 75% objective response rate at the 500 mg once-daily dose when BBO-8520 was combined with pembrolizumab in patients whose lung cancer had already progressed on a prior G12C inhibitor, with a 53% rate across all doses tested, a figure drawn from just 17 patients. BBO-8520 monotherapy posted a 63% response rate in patients who had never taken a G12C inhibitor, with every patient achieving disease control and no grade 3 liver enzyme elevations. The company reported $344.1 million in cash as of June 30, which it says funds operations into 2028, while its second-quarter 2026 net loss widened to $56.5 million from $28.4 million a year earlier and research and development spending nearly doubled to $49.2 million. The two readouts that would most validate the strategic pivot, the expanded BBO-8520 plus pembrolizumab dataset and the colorectal and pancreatic cancer combination results, are not expected until mid-2027, and short interest sits at 21.69% of the float.